Vyjuvek

Vyjuvek (beremagene geperpavec) is a topical gene therapy designed for cutaneous use. It is indicated for the treatment of wounds in patients with dystrophic epidermolysis bullosa. This non-invasive option targets the underlying genetic cause of the condition.

Vyjuvek is used to treat chronic wounds in adults and children with dystrophic epidermolysis bullosa, a rare genetic skin disorder. It works by delivering functional collagen VII protein to promote wound healing. This gene therapy aims to address the root cause of the condition rather than just managing symptoms. Patients and caregivers often seek options for persistent wounds that do not respond to standard care.

When applied to wounds, Vyjuvek may help reduce the size of chronic wounds over time. Users may notice improved skin integrity and faster healing compared to untreated wounds. The effects vary by individual, and consistent application is typically required. Some patients report reduced pain and discomfort in treated areas as wounds begin to close.

Vyjuvek should only be handled by healthcare professionals trained in its application. Avoid direct contact with eyes or mucous membranes during administration. Store the product as directed, typically refrigerated, and protect it from light. Patients with known allergies to any components of the therapy should consult their healthcare provider before use.

No specific drug interactions have been widely reported for Vyjuvek. However, patients using other topical treatments on the same wound area should inform their healthcare provider. Combining Vyjuvek with systemic medications, particularly immunosuppressants, may require careful monitoring. Always disclose all medications and treatments to your healthcare team.